Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Forte Biosciences ( (FBRX) ) just unveiled an announcement.
On June 23, 2025, Forte Biosciences announced positive results from its Phase 1b trial for FB102 in celiac disease, demonstrating significant benefits in histological and symptomatic endpoints. The company plans to initiate a Phase 2 trial with a topline readout expected in 2026, marking a significant step toward addressing unmet needs in celiac disease and potentially benefiting other indications like vitiligo, alopecia areata, and type 1 diabetes.
The most recent analyst rating on (FBRX) stock is a Buy with a $68.75 price target. To see the full list of analyst forecasts on Forte Biosciences stock, see the FBRX Stock Forecast page.
Spark’s Take on FBRX Stock
According to Spark, TipRanks’ AI Analyst, FBRX is a Underperform.
Forte Biosciences faces significant challenges with no revenue and increasing operational losses, leading to a weak financial performance. Technical analysis indicates a mixed outlook with bearish long-term trends. The negative P/E ratio and lack of dividend yield highlight valuation concerns. Without positive developments in these areas, the stock remains highly speculative and risky.
To see Spark’s full report on FBRX stock, click here.
More about Forte Biosciences
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate, for potentially broad autoimmune and autoimmune-related indications.
Average Trading Volume: 47,794
Technical Sentiment Signal: Hold
Current Market Cap: $96.51M
Find detailed analytics on FBRX stock on TipRanks’ Stock Analysis page.